A 24-month, Randomized-control, Double-blind, Multi-center, Delayed-start, Pilot Study Evaluating Thrombin Inhibitions Alzheimer's Disease Using 150mg Dabigatran Daily: A Novel Therapeutic Target for Alzheimer's Disease
Latest Information Update: 22 Apr 2025
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Therapeutic Use
Most Recent Events
- 17 Apr 2025 Planned End Date changed from 1 Dec 2021 to 1 May 2022.
- 17 Apr 2025 Planned primary completion date changed from 1 Nov 2021 to 1 May 2022.
- 17 Apr 2025 Planned initiation date changed from 1 Nov 2018 to 1 May 2019.